CrysvitaActive Ingredient(s): Burosumab
FDA Approved: * April 17, 2018
Pharm Company: * ULTRAGENYX PHARM INC
Category: Genetic Disorders
Burosumab, sold under the brand name Crysvita, is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia. Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018. The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was appro... [wikipedia]* May have multiple approval dates, manufacturers, or labelers.